Lynn D. Kramer
Eisai
66 Papers
238 Citations
Lynn D. Kramer is an academic researcher from Eisai. The author has contributed to research in topics: Medicine & Placebo. The author has an hindex of 17, co-authored 32 publications. Previous affiliations of Lynn D. Kramer include Princeton University.
Chat about Author
Papers
Lecanemab in Early Alzheimer's Disease.
Christopher H. van Dyck,Chad J. Swanson,P. Aisen,Randall J. Bateman,Christopher Chen,Michelle Gee,Michio Kanekiyo,David JianJun Li,Larisa Reyderman,Sharon Cohen,Lutz Froelich,Sadao Katayama,Marwan N. Sabbagh,Bruno Vellas,David Watson,Shobha Dhadda,Michael C Irizarry,Lynn D. Kramer,Takeshi Iwatsubo +18 more
TL;DR: Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils, is being tested in persons with early Alzheimer's disease as mentioned in this paper .
1.3K
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Chad J. Swanson,Yong Zhang,Shobha Dhadda,Jinping Wang,June Kaplow,Robert Lai,Lars Lannfelt,Heather Bradley,Martin Rabe,Akihiko Koyama,Larisa Reyderman,Donald A. Berry,Scott M. Berry,Robert Gordon,Lynn D. Kramer,Jeffrey L. Cummings +15 more
TL;DR: Prespecified 18-month Bayesian and frequentist analyses demonstrated reduction in brain amyloid accompanied by a consistent reduction of clinical decline across several clinical and biomarker endpoints, and a phase 3 study (Clarity AD) in early Alzheimer’s disease is underway.
The β-Secretase BACE1 in Alzheimer's Disease.
Harald Hampel,Robert Vassar,Bart De Strooper,Bart De Strooper,Bart De Strooper,John Hardy,Michael Willem,Neeraj Kumar Singh,John Zhou,Riqiang Yan,Eugeen Vanmechelen,Ann De Vos,Robert Nisticò,Massimo Corbo,Bruno P. Imbimbo,Johannes Streffer,Iryna Voytyuk,Iryna Voytyuk,Iryna Voytyuk,Maarten Timmers,Maarten Timmers,Amir Abbas Tahami Monfared,Amir Abbas Tahami Monfared,Michael C. Irizarry,Bruce Albala,Akihiko Koyama,Naoto Watanabe,Teiji Kimura,Lisa Yarenis,Simone Lista,Simone Lista,Lynn D. Kramer,Andrea Vergallo +32 more
TL;DR: BACE1 concentrations and rates of activity are increased in AD brains and body fluids, thereby supporting the hypothesis that BACE1 plays a critical role in AD pathophysiology, and is a prime drug target for slowing down Aβ production in early AD.
499
•Journal Article
Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome)
Frank J. Ritter,Iio E. Leppik,Fritz E. Dreifuss,Ihor Rak,Nancy Santilli,Roberta Homzie,W. Edwin Dodson,Tracy A. Glauser,J. Chris Sackellares,Larry D. Olson,Elizabeth A. Garafolo,W. Donald Shields,Jacqueline A. French,Michael R. Sperling,Lynn D. Kramer,Marc Kamin,A. Rosenberg,Robert Shumaker,James L. Perhach,Robert Dix +19 more
TL;DR: Felbamate is beneficial in patients with the Lennox-Gastaut syndrome and there was a significant reduction in the number of tonic-clonic seizures during the maintenance period in the felbamate group.
391
Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages
Michael Privitera,R. Fincham,J. Penry,R. Reife,Lynn D. Kramer,Gordon W. Pledger,Rezaul Karim +6 more
TL;DR: Topiramate is a highly efficacious and generally well tolerated new AED and incremental efficacy in the add-on setting is not observed at topiramate dosages above 600 mg/day; however, higher doses may prove beneficial to individual patients who tolerate them.
360